New publication with TLA confirms a significant reduction of severe exacerbations and increased Quality of Life for patients with severe allergic asthma

Airsonett announced today a new publication: “Effect of nocturnal Temperature-controlled Laminar Airflow on the reduction of severe exacerbations in patients with severe allergic asthma: a meta-analysis”1

The study concludes that nocturnal use of TLA (Temperature-controlled Laminar Airflow) shows a beneficial effect on severe exacerbations and quality of life in more symptomatic patients with severe allergic asthma. The patient group with the most severe symptoms showed a significant reduction of severe exacerbations of 48-59%, for TLA compared to placebo.

Professor Leif Bjermer, a co-author, said: “With this publication, we have further confirmed what previous studies have shown; that TLA treatment has a very good effect on both exacerbations and quality of life for multi-sensitised allergic asthma patients that are sensitive to biological stress, with symptoms that are otherwise difficult to control”.

“We are indeed pleased with the results of the study, that further confirms the excellent effects on our patient group. Another important take away from this study is that TLA has a particularly good effect on patients with more severe symptoms. This relatively small patient group represents approximately 40% of asthma treatment costs in health care. We can conclude that this further positions TLA as a very cost-efficient treatment, “says Anders Due-Boje, CEO of Airsonett.

Method of the study: Patients with severe allergic asthma (GINA 4/5) were extracted from two 1-year randomised, double-blind, placebo-controlled trials conducted with TLA. A meta-analysis of the effect on severe exacerbations was performed by negative binomial regression in a sequential manner, defined by baseline markers of asthma control (symptoms and QoL scores).

1: A. J. Chauhan, T. P. Brown, W. Storrar, L. Bjermer, G. Eriksson, F. Radner, S. Peterson & J. O. Warner, European Clinical Respiratory Journal, 10 Mar 2021

2: Clinical documentation for TLA: https://airsonett.eu/clinical-…

For more information:
Anders Due-Boje, CEO, Airsonett AB
Phone: +46 70 526 03 00
E-mail: anders.due-boje@airsonett.eu